Guidewire Software Analysts Raise Their Forecasts After Upbeat Q4 Earnings

Guidewire Software, Inc. (NYSE: GWRE) reported better-than-expected fourth-quarter earnings, but issued soft revenue guidance.

Guidewire Software, Inc. (NYSE:GWRE) reported better-than-expected fourth-quarter earnings, but issued soft revenue guidance.

Guidewire Software posted adjusted earnings of 74 cents per share, beating market estimates of 38 cents per share. The company’s quarterly sales came in at $270.00 million versus expectations of $261.36 million.

Guidewire Software said it sees first-quarter total revenue of $197 million to $202 million, versus estimates of $212.51 million.

Guidewire Software shares jumped 11.7% to trade at $94.72 on Friday.

These analysts made changes to their price targets on Guidewire Software following earnings announcement.

  • Wells Fargo raised the price target on Guidewire Software from $85 to $90. Wells Fargo analyst Michael Turrin maintained an Equal-Weight rating.
  • Stifel increased the price target on Guidewire Software from $85 to $95. Stifel analyst Parker Lane maintained a Buy rating.
  • JP Morgan boosted the price target on Guidewire Software from $83 to $100. JP Morgan analyst Alexei Gogolev maintained an Overweight rating.

Check This Out: Top 5 Health Care Stocks That May Explode In Q3

Total
0
Shares
Related Posts
Read More

Dr. Reddy’s Laboratories Ltd. And Bayer Entered Into A Partnership To Market And Distribute A Second Brand Of Vericiguat In India. Under The Terms Of This Agreement, Bayer Has Granted Non-Exclusive Rights To Dr. Reddy’s Under The Brand Name Gantra

- SEC Filing Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, hereafter referred to as "Dr. Reddy's")) and Bayer announced that both companies have entered into a partnership to

RDY